JPRN-UMIN000018248已完成未知
Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia - Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia
IP lung cancer study group0 个研究点目标入组 40 人开始时间: 2015年7月9日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Secondly interstitial pneumonia. 2) History of acute exacerbation of interstitial pneumonia within 3 months. 3) Subacute progression of interstitial pneumonia within 3 months. 4) Using prednisolone or immune-suppressive agent. 5) Need to home oxygen therapy. 6) Past history of severe drug allergy. 7) Active infectious disease. 8) Severe complications 9) Symptomatic brain metastasis. 10) Uncontrollable effusion. 11) Active combined malignancy 12) Any ineligible case judged by physician.
研究者
相似试验
招募中
不适用
Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniaadvanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniaJPRN-UMIN000018322IP lung cancer study group35
已完成
2 期
Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016)non-small cell lung cancerJPRN-UMIN000006622orth East Japan Study Group36
已完成
1 期
A phase I study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly advanced non-small cell lung canceron-small-cell lung cancerJPRN-UMIN000005263Shimane University Faculty of Medicine, Division of Clinical Oncology and Respiratory Medicine11
已完成
2 期
A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancerThymic cancerJPRN-UMIN000001358West Japan Oncology Group40
已完成
2 期
A clinical trial to study the effects of carboplatin / Paclitaxel and a new drug, CS- 7017, in patients with Non-Small Cell Lung CancerCTRI/2010/091/000491Daiichi Sankyo Pharma Development399 Thornall StreetEdison, NJUSA115